Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1982 1
1983 5
1984 4
1985 7
1986 4
1987 7
1988 3
1989 10
1990 8
1991 13
1992 11
1993 18
1994 9
1995 17
1996 20
1997 38
1998 23
1999 32
2000 33
2001 51
2002 39
2003 45
2004 49
2005 77
2006 80
2007 85
2008 117
2009 140
2010 153
2011 150
2012 197
2013 282
2014 286
2015 311
2016 342
2017 396
2018 444
2019 605
2020 695
2021 794
2022 990
2023 989
2024 563

Text availability

Article attribute

Article type

Publication date

Search Results

7,285 results

Results by year

Filters applied: . Clear all
Page 1
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
Tong X, Patel AS, Kim E, Li H, Chen Y, Li S, Liu S, Dilly J, Kapner KS, Zhang N, Xue Y, Hover L, Mukhopadhyay S, Sherman F, Myndzar K, Sahu P, Gao Y, Li F, Li F, Fang Z, Jin Y, Gao J, Shi M, Sinha S, Chen L, Chen Y, Kheoh T, Yang W, Yanai I, Moreira AL, Velcheti V, Neel BG, Hu L, Christensen JG, Olson P, Gao D, Zhang MQ, Aguirre AJ, Wong KK, Ji H. Tong X, et al. Among authors: fang z. Cancer Cell. 2024 Mar 11;42(3):413-428.e7. doi: 10.1016/j.ccell.2024.01.012. Epub 2024 Feb 22. Cancer Cell. 2024. PMID: 38402609 Free article.
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.
Qin Z, Yue M, Tang S, Wu F, Sun H, Li Y, Zhang Y, Izumi H, Huang H, Wang W, Xue Y, Tong X, Mori S, Taki T, Goto K, Jin Y, Li F, Li FM, Gao Y, Fang Z, Fang Y, Hu L, Yan X, Xu G, Chen H, Kobayashi SS, Ventura A, Wong KK, Zhu X, Chen L, Ren S, Chen LN, Ji H. Qin Z, et al. Among authors: fang z. J Exp Med. 2024 Mar 4;221(3):e20232028. doi: 10.1084/jem.20232028. Epub 2024 Jan 29. J Exp Med. 2024. PMID: 38284990
GTF2H4 regulates partial EndMT via NF-κB activation through NCOA3 phosphorylation in ischemic diseases.
Fang Z, Zhao G, Zhao S, Yu X, Feng R, Zhang YE, Li H, Huang L, Guo Z, Zhang Z, Abdurahman M, Hong H, Li P, Wu B, Zhu J, Zhong X, Huang D, Lu H, Zhao X, Chen Z, Zhang W, Guo J, Zheng H, He Y, Qin S, Lu H, Zhao Y, Wang X, Ge J, Li H. Fang Z, et al. Innovation (Camb). 2024 Jan 8;5(2):100565. doi: 10.1016/j.xinn.2024.100565. eCollection 2024 Mar 4. Innovation (Camb). 2024. PMID: 38379791 Free PMC article.
The role of ferroptosis in cardio-oncology.
Hou K, Liu L, Fang ZH, Zong WX, Sun D, Guo Z, Cao L. Hou K, et al. Among authors: fang zh. Arch Toxicol. 2024 Mar;98(3):709-734. doi: 10.1007/s00204-023-03665-3. Epub 2024 Jan 5. Arch Toxicol. 2024. PMID: 38182913 Review.
BCG vaccination stimulates integrated organ immunity by feedback of the adaptive immune response to imprint prolonged innate antiviral resistance.
Lee A, Floyd K, Wu S, Fang Z, Tan TK, Froggatt HM, Powers JM, Leist SR, Gully KL, Hubbard ML, Li C, Hui H, Scoville D, Ruggiero AD, Liang Y, Pavenko A, Lujan V, Baric RS, Nolan GP, Arunachalam PS, Suthar MS, Pulendran B. Lee A, et al. Among authors: fang z. Nat Immunol. 2024 Jan;25(1):41-53. doi: 10.1038/s41590-023-01700-0. Epub 2023 Nov 30. Nat Immunol. 2024. PMID: 38036767
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial.
Li K, Chen J, Hu Y, Wang YZ, Shen Y, Chen G, Peng W, Fang Z, Xia B, Chen X, Song K, Wang Y, Zou D, Wang YC, Han Y, Feng X, Yuan J, Guo S, Meng X, Feng C, Chen Y, Yang J, Fan J, Wang J, Ai J, Ma D, Sun C. Li K, et al. Among authors: fang z. Lancet Oncol. 2024 Jan;25(1):76-85. doi: 10.1016/S1470-2045(23)00531-4. Epub 2023 Dec 1. Lancet Oncol. 2024. PMID: 38048802 Clinical Trial.
7,285 results